On Jun. 12, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had approved Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for treatment of human immunodeficiency virus type 1 infection in paediatric patients (treatment-na�ve or -experienced but INSTI- na�ve) aged at least four weeks and weighing at least 3kg, as well as an extended indication to expand the use of the already approved Tivicay (dolutegravir) 50mg film-coated tablet in paediatric HIV patients weighing 20kg and above.